Non Alcoholic Fatty Liver Disease (NAFLD) is an emergent disease worldwide, and soon the leading cause of hepatic transplant in the USA. Among this high number of patients, the current challenge is to detect or even predict patients at risk of inflammation (Non Alcoholic or Steatohepatitis or NASH) and end-stage fibrosis, which are the best predictors of liver-related mortality. Visceral obesity is intimately associated with metabolic disease and adverse health outcomes, such as diabetes, and NAFLD. It has been demonstrated that visceral adipose tissue-linked inflammation was a risk factor of stroke, myocardial infarction, and others metabolic-related complications. The aim of this study was to evaluate the association of the quantity and percentage of Visceral Adipose Tissue by Dual X-Ray Absorptiometry and liver stiffness by Fibroscan in patients with type 2 diabetes, and other predictors of fibrosis such as FIB-4 and Fibrotest. We retrospectively collected the data of all the diabetic patients who had undergone a DEXA and a Fibroscan between January 1st, 2014 and Decembre 31th, 2019, in the Universitary Hospital of Nancy, France.
Study Type
OBSERVATIONAL
Enrollment
86
GUERCI Bruno
Nancy, France
Association between quantity of Visceral adipose Tissu and Liver Stiffness
Visceral adipose tissu in grams mesured by DEXA, and Liver stiffness in kiloPascal mesured par Vibration-Controlled Transient Elastography
Time frame: July to September 2020
Association between percentage of Visceral adipose Tissu and Liver Stiffness
Visceral adipose tissu in percentage on total fat mass mesured by DEXA, and Liver stiffness in kiloPascal mesured par Vibration-Controlled Transient Elastography
Time frame: July to September 2020
Association between quantity of Visceral adipose Tissue and histologic Fibrosis
Visceral adipose tissu in grams mesured by DEXA, and histologic fibrosis determined on hepatic biopsy.
Time frame: July to September 2020
Association between percentage of Visceral adipose Tissue and histologic Fibrosis
Visceral adipose tissu percentage on total fat mass mesured by DEXA, and histologic fibrosis determined on hepatic biopsy.
Time frame: July to September 2020
Determine the diagnostic performances of quantity of Visceral adipose Tissue for histologic fibrosis diagnosis.
Visceral adipose tissu in grams mesured by DEXA, and histologic fibrosis determined on hepatic biopsy.
Time frame: July to September 2020
Determine the diagnostic performances of percentage of Visceral adipose Tissue for histologic fibrosis diagnosis.
Visceral adipose tissu percentage on total fat mass mesured by DEXA, and histologic fibrosis determined on hepatic biopsy.
Time frame: July to September 2020
Determine the diagnostic performances of different biologic markers for histologic fibrosis diagnosis.
Histologic fibrosis determined on hepatic biopsy.
Time frame: July to September 2020
Build an algorithm with Visceral adipose Tissue mesured and biological markers to predict fibrosis.
Prediction algorithm for hepatic fibrosis based on different markers
Time frame: July to September 2020
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.